secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImmunityBio, Inc. (IBRX)
CIK:        0001326110
Form:       8-K
Filed at:   2025-03-03T23:59:59+00:00
Accession:  0001326110-25-000031
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmunityBio Q4 net product revenue $7.2M; Feb ANKTIVA units up 67% MoM; RMAT designation granted
--------------------------------------------------------------------------------

- Net product revenue $7.2M in Q4 2024, up 21% QoQ from $6.0M in Q3; full-year net product revenue $14.2M.
- ANKTIVA February 2025 unit sales up 67% month-over-month from January; Jan+Feb combined exceed total Q4 2024 units.
- Permanent J-code (J9028) issued Jan 2025; FDA authorized expanded access of rBCG with over 45,000 vials available and 60+ sites activating.
- MAAs for ANKTIVA+BCG accepted by MHRA and EMA in Feb 2025; RMAT designation for ANKTIVA+PD-L1 t-haNK in pancreatic cancer.
- Net loss attributable to common stockholders narrowed to $59.2M in Q4 2024 from $233.4M in Q4 2023; cash and securities $149.8M at Dec 31.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326110/000132611025000031/0001326110-25-000031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326110/000132611025000031/ibrx-20250303.htm
  HTML page:      https://secwatch.observer/filing/0001326110-25-000031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer